SEHK:2696Biotechs
Assessing Shanghai Henlius Biotech (SEHK:2696) Valuation After HLX37 Enters Phase 1 Clinical Study
Shanghai Henlius Biotech (SEHK:2696) has dosed the first patient in its phase 1 trial of HLX37, a bispecific antibody that targets PD-L1 and VEGF in advanced or metastatic solid tumours in Mainland China.
See our latest analysis for Shanghai Henlius Biotech.
The HLX37 trial update comes after a mixed stretch for the stock, with a 1-day share price return of 2.00% and a 7-day share price return of 11.92% but a 90-day share price return of 15.71%. However, the 1-year total shareholder return of...